Cancer drug shows promise in keeping sarcoma in check

NCT ID NCT03793361

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether the drug regorafenib (Stivarga) could help keep metastatic soft tissue sarcoma from growing after initial chemotherapy. 127 adults whose cancer was stable or shrinking after six cycles of doxorubicin-based chemo were randomly assigned to receive either regorafenib or a placebo. The study found that regorafenib delayed cancer progression compared to placebo, suggesting it may be a useful maintenance therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib (Stivarga)
What this could lead to: If successful, this could offer a new maintenance option to delay cancer progression in people with metastatic soft tissue sarcoma after initial chemotherapy.
What could go wrong: This is a phase 2 trial with 127 participants, so results are preliminary. Regorafenib can cause side effects like fatigue, diarrhea, and high blood pressure. The benefit in overall survival is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOFT-TISSUE SARCOMA

Contacts and locations

Locations

CHRU Besançon

Besançon, 25000, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre Eugène Marquis

Rennes, 35042, France
Centre François Baclesse

Caen, 14076, France
Centre Georges-François LECLERC

Dijon, 21079, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Centre René Gauducheau

Nantes, 44805, France
Chu Poitiers

Poitiers, 86000, France
Hôpital La Timone

Marseille, 13005, France
Hôpitaux universitaires de Strasbourg

Strasbourg, 67000, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Curie

Paris, 75005, France
Institut Godinot

Reims, 51100, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut Paoli-Calmettes

Marseille, 13273, France
Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, 42270, France
Institut régional du Cancer de Montpellier

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.